fluoxetine

Claims are circulating that the medical evidence supporting Prozac (fluoxetine) as a treatment for depression in children and adolescents rests largely on a single clinical trial with methodological flaws, meaning the drug's effectiveness for young patients may have been overstated. Commenters are questioning how such a foundational study shaped prescribing guidance for pediatric depression.

A Nature report argues that widespread prescribing of Prozac (fluoxetine) for childhood depression rests largely on one early clinical trial now judged methodologically flawed. Commentators say the finding raises questions about how a single weak study shaped decades of treatment guidance for adolescents, and are calling for re-examination of the evidence base behind paediatric antidepressant use.